What You'll Want to Know About Geron's Q2 Results
Investors weren't too happy the last time Geron (NASDAQ: GERN) announced quarterly results in May. Revenue dropped 82%, and the small biotech's net loss widened. Later in the month, Geron disappointed investors even more with its announcement of a delay in the decision regarding imetelstat's potential development as a treatment for patients with myelofibrosis who are at "intermediate-2" or high risk.
Anyone hoping for great news from Geron when the company reported its Q2 earnings release on Thursday after the market closed were let down yet again. Here's what you need to know from the biotech's Q2 update.
Image source: Getty Images.
Quelle Fool.com
